PDE4B

cAMP-specific 3',5'-cyclic phosphodiesterase 4B is an enzyme that in humans is encoded by the PDE4B gene.^[5]

PDE4B
Available structures PDB Human UniProt search: PDBe RCSB List of PDB id codes 1F0J, 1RO6, 1RO9, 1ROR, 1TB5, 1XLX, 1XLZ, 1XM4, 1XM6, 1XMU, 1XMY, 1XN0, 1XOS, 1XOT, 1Y2H, 1Y2J, 2CHM, 2QYL, 3D3P, 3FRG, 3G45, 3GWT, 3HC8, 3HDZ, 3HMV, 3KKT, 3LY2, 3O0J, 3O56, 3O57, 3W5E, 3WD9, 4KP6, 4MYQ, 4NW7, 4WZI, 4X0F
Identifiers
Aliases	PDE4B, DPDE4, PDEIVB, phosphodiesterase 4B
External IDs	OMIM: 600127; MGI: 99557; HomoloGene: 1953; GeneCards: PDE4B; OMA:PDE4B - orthologs
Gene location (Human) Chr. Chromosome 1 (human)[1] Band 1p31.3 Start 65,792,514 bp[1] End 66,374,579 bp[1]
Gene location (Mouse) Chr. Chromosome 4 (mouse)[2] Band 4 C6|4 46.99 cM Start 101,944,740 bp[2] End 102,464,456 bp[2]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in corpus callosum cartilage tissue subthalamic nucleus inferior ganglion of vagus nerve superior vestibular nucleus ventral tegmental area external globus pallidus middle temporal gyrus pars reticulata Pons Top expressed in left lung lobe nucleus accumbens olfactory tubercle supraoptic nucleus dorsal striatum triceps brachii muscle muscle of thigh medial head of gastrocnemius muscle temporal muscle vastus lateralis muscle More reference expression data BioGPS More reference expression data
Gene ontology Molecular function metal ion binding 3',5'-cyclic-nucleotide phosphodiesterase activity hydrolase activity cAMP binding gamma-tubulin binding transmembrane transporter binding phosphoric diester hydrolase activity 3',5'-cyclic-AMP phosphodiesterase activity protein binding Cellular component voltage-gated calcium channel complex gamma-tubulin complex cell periphery cytosol postsynaptic density dendritic spine membrane centrosome Z discdkac excitatory synapse synaptic vesicle Biological process regulation of high voltage-gated calcium channel activity neutrophil homeostasis regulation of cardiac muscle cell contraction positive regulation of interferon-gamma production signal transduction cellular response to lipopolysaccharide positive regulation of interleukin-2 production leukocyte migration negative regulation of relaxation of cardiac muscle cellular response to epinephrine stimulus T cell receptor signaling pathway neutrophil chemotaxis cAMP catabolic process G protein-coupled receptor signaling pathway Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 5142 18578 Ensembl ENSG00000184588 ENSMUSG00000028525 UniProt Q07343 n/a RefSeq (mRNA) NM_001037339 NM_001037340 NM_001037341 NM_001297440 NM_001297441 NM_001297442 NM_002600 NM_001177980 NM_001177981 NM_001177982 NM_001177983 NM_019840 NM_001374780 RefSeq (protein) NP_001032416 NP_001032417 NP_001032418 NP_001284369 NP_001284370 NP_001284371 NP_002591 NP_001032418.1 NP_002591.2 n/a Location (UCSC) Chr 1: 65.79 – 66.37 Mb Chr 4: 101.94 – 102.46 Mb PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

This gene is a member of the type IV, cyclic AMP (cAMP)-specific, cyclic nucleotide phosphodiesterase (PDE) family. Cyclic nucleotides are important second messengers that regulate and mediate a number of cellular responses to extracellular signals, such as hormones, light, and neurotransmitters. The cyclic nucleotide phosphodiesterases (PDEs) regulate the cellular concentrations of cyclic nucleotides and thereby play a role in signal transduction. This gene encodes a protein that specifically hydrolyzes cAMP. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.^[5][6]

Clinical relevance

Altered activity of this protein has been associated with schizophrenia and bipolar disorder.^[5] PDE4B is believed to be the PDE4 subtype involved in the antipsychotic effects of PDE4 inhibitors such as rolipram.^[7] PDE4B is involved in dopamine-associated and stress-related behaviours.^[8] It has also recently been found to modulate cognition, as reduction in PDE4B activity improves memory and long-term plasticity in mouse models, possibly supporting further therapeutic applications.^[9]

Inhibitors

Crisaborole, a boron-containing drug was approved by the FDA in 2016 for the treatment of atopic dermatitis, and as of 2024 is being commercialized by Pfizer under the name of Eucrisa (chemical name: 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile) mainly acting on PDE4B. ^[10][11][12]